Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease
Abstract Background Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle. The known triggers for complement activation can be di...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-09-01
|
| Series: | Thrombosis Journal |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12959-019-0207-7 |